Identifying Diagnostic Markers in Patients with Metastatic Cancer
Integrated Genomics and Patient-Derived Cancer Models
Mayo Clinic · NCT05530759
This study is trying to find new markers in blood and tissue samples from patients with metastatic cancer to see if they can help guide better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05530759 on ClinicalTrials.gov |
What this trial studies
This study examines blood and tissue samples from patients with metastatic cancer undergoing tumor removal to identify diagnostic markers and potential therapeutic targets. It focuses on analyzing DNA and protein changes in biopsies and tumors to understand the molecular mechanisms of malignancies. By integrating genomic data, the study aims to discover pathways involved in tumor progression and assess the effectiveness of targeted individualized therapies based on these findings. The research involves collecting samples before or after standard care procedures and reviewing patients' medical records.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of malignancy who are suitable for standard biopsy or surgical procedures.
Not a fit: Patients with uncontrolled illnesses or those whose tumors are inaccessible for biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with aggressive metastatic cancers.
How similar studies have performed: Other studies have shown promise in using genomic and proteomic analyses to identify biomarkers and improve treatment strategies, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients (or the legally authorized representative/guardian signing on behalf of the participant) must understand and provide written informed consent prior to initiation of any study-specific procedures * \>= 18 years of age * Patients must have a diagnosis of confirmed malignancy * Patient is a good medical candidate for a standard of care biopsy or surgical procedure to obtain tissue or has archival tissue available for analysis Exclusion Criteria: * Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent * Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use * Biopsy must not be considered to be more than minimal risk to the patient. Contraindications to percutaneous biopsy: * Significant coagulopathy that cannot be adequately corrected * Severely compromised cardiopulmonary function or hemodynamic instability * Lack of a safe pathway to the lesion * Inability of the patient to cooperate with, or to be positioned for, the procedure
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Aaron S. Mansfield, M.D. — Mayo Clinic in Rochester
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm